PUBLISHER: The Business Research Company | PRODUCT CODE: 1945324
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945324
House dust mite allergy refers to an allergic reaction triggered by small insects commonly found in household dust. This encompasses the treatment methods employed to address allergic responses such as sneezing and other allergy-related conditions.
The primary product types for managing house dust mite allergy include tablets, nasal drops, and injectables. Tablets represent a compact, solid-dose form that may contain medications with or without excipients. Treatment modalities encompass medication, immunotherapy, nasal irrigation, and other approaches. Diagnosis involves methods such as the skin prick test (SPT) and specific immunoglobulin E (IgE) blood test, among others, utilizing various dosage forms such as solid and liquid. These products find application across diverse end-users, including hospitals, homecare settings, specialty clinics, and others.
Tariffs are impacting the house dust mite allergy market by increasing costs of imported pharmaceutical ingredients, diagnostic kits, immunotherapy formulations, and medical testing equipment. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported allergy treatments, while Asia-Pacific faces pricing pressure on pharmaceutical exports. These tariffs are raising treatment costs and diagnostic expenses. However, they are also encouraging local drug manufacturing, regional diagnostic kit production, and increased investment in domestic allergy treatment solutions.
The house dust mite allergy market research report is one of a series of new reports from The Business Research Company that provides house dust mite allergy market statistics, including house dust mite allergy industry global market size, regional shares, competitors with a house dust mite allergy market share, detailed house dust mite allergy market segments, market trends and opportunities, and any further data you may need to thrive in the house dust mite allergy industry. This house dust mite allergy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The house dust mite allergy market size has grown rapidly in recent years. It will grow from $2.37 billion in 2025 to $2.7 billion in 2026 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to rising prevalence of allergic conditions, increased awareness of respiratory allergies, expansion of diagnostic testing availability, growing use of antihistamine medications, improvements in allergy treatment protocols.
The house dust mite allergy market size is expected to see rapid growth in the next few years. It will grow to $4.62 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to increasing adoption of personalized immunotherapy, rising focus on preventive allergy care, expansion of home-based allergy management, growing demand for long-term symptom control, advancements in biologic allergy treatments. Major trends in the forecast period include increasing adoption of immunotherapy-based treatments, rising use of sublingual allergy tablets, growing demand for long-term allergy management solutions, expansion of early diagnostic testing adoption, enhanced focus on personalized allergy treatment.
The increasing incidence of asthma diseases is anticipated to support the growth of the house dust mite allergy market in the coming years. Asthma diseases are chronic inflammatory conditions of the airways marked by recurrent symptoms such as shortness of breath, wheezing, chest tightness, and coughing. The prevalence of asthma is rising largely due to escalating environmental pollution, which aggravates airway inflammation and increases sensitivity to airborne allergens. As asthma cases continue to expand rapidly, demand within the house dust mite allergy market is increasing, prompting companies to adopt solutions that help minimize allergen exposure and improve respiratory health outcomes. For example, in June 2025, according to the American Lung Association, a United States-based nonprofit health organization, asthma prevalence among adults varied significantly across United States jurisdictions in 2023, ranging from 7.1% in Mississippi to 14.1% in Puerto Rico. Therefore, the growing prevalence of asthma diseases is driving demand for house dust mite allergy-related solutions.
Major companies in the house dust mite allergy market are concentrating on developing innovative solutions, such as sublingual tablets aimed at treating house dust mite allergies, to tackle the rising prevalence of these allergies. A sublingual tablet for treating house dust mite allergies is a form of immunotherapy where a tablet is placed under the tongue, allowing it to dissolve and release small doses of the allergen that triggers the allergy. For example, in January 2023, ALK-Abello A/S, a pharmaceutical company based in Denmark, received FDA approval for ODACTRA, a sublingual tablet designed for adolescents aged 12 to 17, thereby expanding its previous indication for adults. This approval meets a critical need, as nearly 50% of allergy sufferers are sensitive to house dust mites. Clinical trials showed that ODACTRA effectively alleviated allergy symptoms and had a safety profile comparable to that seen in adults. Although the treatment is generally well-tolerated, patients are advised to keep auto-injectable epinephrine available due to the risk of severe allergic reactions.
In September 2025, Stallergenes Greer, a France-based biopharmaceutical company specializing in allergen immunotherapy, entered into a partnership with Nuance Pharma to broaden the commercialization of its house dust mite sublingual immunotherapy tablet, Actair, across China. Through this collaboration, the companies seek to enhance access to evidence-based allergy treatments and reinforce the availability of advanced immunotherapy options for patients suffering from house dust mite-induced allergic rhinitis. Nuance Pharma is a China-based biopharmaceutical company focused on respiratory, immunology, and specialty-care therapeutics.
Major companies operating in the house dust mite allergy market are Allergy Therapeutics Plc, Bayer AG, Catalent Inc., GSK Plc, Merz Pharma GmbH & Co KGaA, Sanofi S A, Shionogi & Co. Ltd., Stallergenes Greer International AG, Merck & Co. Inc., Torii Pharmaceutical Co. Ltd., Ergomed PLC, DMS Group, HAL Allergy Group, Trio Lifescience Private Limited, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Johnson and Johnson Inc., Circassia Pharmaceuticals Plc, Biomay Ag, GlaxoSmithKline
North America was the largest region in the house dust mite allergy market in 2025. Asia-pacific is expected to be the fastest-growing region in the house dust mite allergy market report during the forecast period. The regions covered in the house dust mite allergy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the house dust mite allergy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The house dust mite allergy market consists of sales of prescription drugs and over-the-counter drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
House Dust Mite Allergy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses house dust mite allergy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for house dust mite allergy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The house dust mite allergy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.